Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Artificial intelligence image analysis for Hounsfield units in preoperative thoracolumbar CT scans: an automated screening for osteoporosis in patients undergoing spine surgery
Feng, Emily , Machlab, Laura A., Freedman, Brett A. , Bydon, Mohamad , Jayasuriya, Nishantha M, Katsos, Konstantinos, Jayasuriya, Nishantha M., Nathani, Karim Rizwan , Katsos, Konstantinos D. , Johnson, Graham W. , Freedman, Brett A.

Mayo Clinic

Journal of Neurosurgery: Spine | April 18, 2025 | Volume: 43 | Issue: 1 | Pages: 1-8

10.3171/2025.1.spine24900 | PMID 40250051 Get It

OBJECTIVE This study aimed to develop an artificial intelligence (AI) model for automatically detecting Hounsfield unit (HU) values at the L1 vertebra in preoperative thoracolumbar CT scans. This model serves as a screening tool for osteoporosis in patients undergoing spine surgery, offering an alternative to traditional bone mineral density measurement methods like dual-energy x-ray absorptiometry. METHODS The authors utilized two CT scan datasets, comprising 501 images, which were split into training, validation, and test subsets. The nnU-Net framework was used for segmentation, followed by an algorithm to calculate HU values from the L1 vertebra. The model’s performance was validated against manual HU calculations by expert raters on 56 CT scans. Statistical measures included the Dice coefficient, Pearson correlation coefficient, intraclass correlation coefficient (ICC), and Bland-Altman plots to assess the agreement between AI and human-derived HU measurements. RESULTS The AI model achieved a high Dice coefficient of 0.91 for vertebral segmentation. The Pearson correlation coefficient between AI-derived HU and human-derived HU values was 0.96, indicating strong agreement. ICC values for interrater reliability were 0.95 and 0.94 for raters 1 and 2, respectively. The mean difference between AI and human HU values was 7.0 HU, with limits of agreement ranging from −21.1 to 35.2 HU. A paired t-test showed no significant difference between AI and human measurements (p = 0.21). CONCLUSIONS The AI model demonstrated strong agreement with human experts in measuring HU values, validating its potential as a reliable tool for automated osteoporosis screening in spine surgery patients. This approach can enhance preoperative risk assessment and perioperative bone health optimization. Future research should focus on external validation and inclusion of diverse patient demographics to ensure broader applicability.
Child Sexual Abuse Module in the Child Abuse Pediatrics Curriculum for Physicians (CAP-CuP)
Bangash, Maheen, Crumm, Caitlin E. , Brown, Emily , Petska, Hillary W., Frank, Lauren R., Sheets, Lynn K. , Johnson, Katie L. , Bangash, Maheen K

Mayo Clinic

MedEdPORTAL | April 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11515 | PMID 40255580 Get It

A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn’s disease
Johnson, Amanda M. , Askar, Manar, Belani, Seema, Xu, Anthony , Kassmeyer, Blake , Said, Hyder , Santiago-Castro, Michael, Devi, Jalpa , Huang, Katherine , Jaiprada, Fnu, Seth, Nickhil, Dulaney, David , Fenster, Marc, Shukla, Richa, Yarur, Andrés , Santiago-Castro, Michael , Devi, Jalpa , Bishu, Shrinivas , Ungaro, Ryan , Deepak, Parakkal , Yarur, Andres J , Khan, Abdul Wali , Seth, Nickhil, Loftus, Edward V. , Patel, Anish A , Bishu, Shrinivas , Ungaro, Ryan C. , Shukla, Richa, Deepak, Parakkal

Mayo Clinic

Journal of Crohn's and Colitis | April 18, 2025 | Volume: 19 | Issue: 5 | Pages: No page available

10.1093/ecco-jcc/jjaf070 | PMID 40289770 Get It

Abstract Background We aimed to evaluate the effectiveness and safety of risankizumab (RZB) for Crohn’s disease (CD) in routine clinical practice. Methods We performed a retrospective review of a multicenter consortium of CD patients treated with RZB. Co-primary outcomes were week 12 clinical remission (Harvey Bradshaw Index [HBI] score of ≤4 or physician global assessment in those without HBI or with ileostomy) and 6-month endoscopic remission (Simplified Endoscopic Mucosal Assessment for Crohn’s Disease of 0-1 or absence of ulcers). Secondary outcomes included steroid-free clinical remission, clinical response, radiographic response, cumulative clinical and endoscopic remission rates at 6 and 12 months, and adverse events. Results A total of 309 patients were included (median disease duration 14 years [IQR, 6-24]; median follow-up 7.1 months [IQR, 4.1-10.3]). Most patients (85.8%) were advanced therapy (AT)-exposed, and 169 (54.7%) had prior ustekinumab (UST) exposure. Week 12 clinical remission rates were 49.7% (98/197) overall, and 44.2% (50/113) vs 57.1% (48/84) in UST-exposed vs naïve patients (P = .073). Among those with active disease on baseline endoscopy (n = 122) who had an available follow-up at 6 months, 52.4% (22/42) achieved endoscopic remission. Cumulative rates of clinical and endoscopic remission at 12 months were 65.0% and 49.5%, respectively. Cumulative 12-month endoscopic remission was 33.9% (19/56) in UST-exposed and 68.1% (32/47) in UST-naïve patients (P < .001). Risankizumab was well-tolerated with no new safety signals identified. Conclusions In this large multicenter cohort of patients with CD, RZB was well-tolerated and effective in achieving favorable clinical and endoscopic outcomes in both AT-exposed and naïve populations, including those with exposure to UST.
Pineal parenchymal tumor of intermediate differentiation: Case series and literature review: Is it time for a consensus?
Srinivasan, Siddharth , Jampani, Ravi Teja, Chigurupati, Dhanwanth, Raju, Bharat , Subramanian, Susanth , Baxi, Udgam, Kanneganti, Yasaswi, Johnson, Sarah H. , Nayal, Bhavna, Vasudevan, Geetha , M, Deepak Nayak , Johnson, Sarah, Hegde, Ajay , Nair, Rajesh Parameshwaran , Ashraf, Mohammad, Menon, Girish

Mayo Clinic

Surgical Neurology International | April 18, 2025 | Volume: 16 | Issue: No issue available | Pages: 138

10.25259/sni_1068_2024 | PMID 40353160 Get It

Background Pineal parenchymal tumor of intermediate differentiation (PPTID) is a rare tumor. This study aims to evaluate patient outcomes and propose a treatment algorithm based on existing literature and our case series. Methods This prospective observational study includes seven patients diagnosed with PPTID through histopathology. We analyzed their clinical presentation, magnetic resonance imaging findings, surgical approaches, histopathological and immunohistochemical analysis, adjuvant treatments, and outcomes. We conducted univariate and multivariate statistical analyses. Results The mean patient age was 40 years, with a male predominance. All patients presented with hydrocephalus, four of which required cerebrospinal fluid diversion procedures. The average tumor size was 3.13cm, with 85.7% showing brain invasion. Surgical outcomes included one gross total resection, two near total resections, and four subtotal resections. The supracerebellar infratentorial (Krause) approach was used in 71.4% of cases. About 85.7% were diagnosed with grade 3 PPTID. Five patients received adjuvant radiotherapy. The analysis showed each additional mitosis unit decreased survival by 0.17 units, equating to roughly 2 months (P < 0.016). Follow-up ranged from 6 to 120 months, with a 5-year survival rate of 57.1%. Factors influencing survival included the extent of tumor resection, brain invasion, tumor grade, and adjuvant treatment, although it was not statistically significant due to the small sample size. Conclusion We propose a treatment algorithm for PPTID and highlight the importance of further research to understand its biological characteristics. Safe maximal resection appears beneficial for higher-grade PPTID, but the role of adjuvant treatment after complete resection of lower-grade tumors remains uncertain.
Abstract MP24: Socioeconomic Disparities in Cardiac Rehabilitation Perceptions and Delivery Mode Preferences: A Nationally Representative Survey Among Diverse Cardiac Patients.
Anyetei-Anum, Grace Patrice, Averkamp, Natalie , Johnson, Matthew P. , Krogman, Ashton , Clark, Donald , Echols, Melvin , Hall, Michael E. , Hodgman, Karen, Kaihoi, Brian, Kopecky, Stephen L. , Leth, Shawn , Malik, Shaista , Scales, Robert , Shultz, Adam M. , Schulte, Phillip J. , Olson, Thomas P. , Abraham, Helayna , Marsteller, Jill , Mathews, Lena , Taylor, Bryan J. , Thomas, Randal J. , Wong, Nathan D. , Brewer, LaPrincess C.

Mayo Clinic

Circulation | April 17, 2025 | Volume: 151 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.151.suppl_1.mp24 Get It

Background: Cardiac rehabilitation (CR) is essential to secondary cardiovascular disease prevention and management of cardiac patients. Despite its proven benefits, CR remains underutilized with enrollment and completion rates ranging from 10-30% in the US. Yet, there is a scarcity of nationally representative data among diverse populations on socioeconomic differences in barriers and beliefs of CR participation and delivery mode preferences. Hypothesis: The perceptions (barriers, beliefs), CR delivery mode preferences, and CR utilization (prior enrollment) varies by socioeconomic status (SES) among CR-eligible individuals. Methods: We conducted an anonymous national electronic survey from March 2023 to January 2024 of individuals self-reporting a prior CR-eligible diagnosis. The 22-item CR Barriers Scale assessed perceived barriers to CR enrollment and participation using a 5-point Likert scale (strongly disagree to strongly agree). A 13-item, validated questionnaire assessed 4 subscales pertaining to patients’ beliefs about CR, each rated on a 5-point Likert scale (strongly disagree to strongly agree): perceived necessity, concerns about exercise, practical barriers and perceived suitability. CR delivery mode preferences were ascertained (eg, virtual, at-home, etc.). Mean barriers and belief scores as well as delivery mode preferences were stratified by SES. Low SES was defined as ≤ high school education, Medicaid insurance, or uninsured. High SES was defined as > high school education and non-Medicaid health insurance. Responses were analyzed using descriptive statistics with R software. Results: A total of 466 participants completed the survey (38.1% women, 30.6% minoritized racial/ethnic group, 29.6% low SES, 95% response rate) ( Table 1 ). The majority indicated prior enrollment in CR (81.5%) with no difference by SES. CR barrier scores did not differ significantly by SES (p=0.331) ( Table 2 ). Beliefs about CR perceived necessity and perceived suitability differed by SES (p<0.001 and p=0.025), but beliefs regarding concerns about exercise and practical barriers did not. The low SES group reported a higher preference for completely at-home CR compared to the high SES group (33.6% vs 7.4%, p<0.001). Conclusion: Our findings suggest that CR beliefs varied by SES while utilization did not. For CR-eligible patients experiencing socioeconomic disadvantage, at-home CR may be a preferred alternative to center-based CR to increase CR participation and adherence.
Abstract P1062: Pre-Pandemic Thrombo-inflammatory Biomarkers and Risk of Severe Covid-19: the Collaborative Cohort of Cohorts for Covid-19 Research (C4R)
Cushman, Mary , Choi, Yuni , Reiner, Alex P. , Mukaz, Debora Kamin , Xanthakis, Vanessa, Johnson, Andrew D. , Umans, Jason G. , Kandula, Namratha R. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Jacobs, David R. , Demmer, Ryan T. , Tracy, Russell P. , Olson, Nels C. , Doyle, Margaret F. , Raffield, Laura M. , Min, Yuan‐I , Vasan, Ramachandran S. , Xanthakis, Vanessa , Make, Barry J. , Regan, Elizabeth Anne , Bowler, Russell P. , Thyagarajan, Bharat

Mayo Clinic

Circulation | April 17, 2025 | Volume: 151 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.151.suppl_1.p1062 Get It

Background: Thrombo-inflammation is a hallmark of acute Covid-19, with higher thrombo-inflammatory markers during infection associated with adverse outcomes. We hypothesized that higher pre-pandemic biomarkers, reflecting a higher thrombo-inflammatory setpoint, might identify people at greater risk of severe manifestations of Covid-19. Hypothesis: Pre-pandemic inflammation markers are associated with risk of hospitalized or fatal (hereafter, “severe”) Covid-19 in a multi-ethnic US sample. Methods: From 2020-2023, C4R harmonized pre-pandemic measures and ascertained Covid-19 across 14 longstanding cohort studies. In 12 cohorts, we assessed biomarker data and covariates from the study visit closest to the pandemic for 6 analytes shown in the Table. HRs of severe Covid-19 by pre-pandemic biomarkers were estimated using cause-specific Cox regression, treating non-severe Covid-19 as a competing risk, and adjusting for pre-pandemic sociodemographic and clinical characteristics. Results: Biomarkers were measured a mean of 20 years before the pandemic with different sample sizes for each (Table footnote). Mean age at the start of the pandemic was in the 60s or 70s depending on the biomarker. The most represented race or ethnic groups were White and Black. The largest sample was for C-reactive protein, and there were 1,001 severe Covid-19 cases among 38,784 participants. In the adjusted models, considered individually, higher CRP, leukocyte count, factor VIII and fibrinogen, but not other markers, were associated with greater risk of severe Covid-19 (Table).Associations were robust across subgroups and time since biomarker measurement (example for C-reactive protein in Figure). Conclusions: In this prospective multi-study analysis of a multi-ethnic population, higher basal levels of thrombo-inflammation markers were associated with greater risk of severe Covid-19. Since we considered non-severe Covid-19 as a competing risk, associations may reflect factors related to progression to more serious Covid-19 illness.
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Block, Matthew S. , Nelson, Garth D. , Chen, Jun , Johnson, Stephen , Yang, Lu , Flotte, Thomas J. , Grewal, Eric P. , McWilliams, Robert R. , Kottschade, Lisa A. , Domingo‐Musibay, Evidio , Montane, Heather N. , Hui, Jane Yuet Ching , Erskine, Courtney L. , Zahrieh, David , Flotte, Thomas James , Markovic, Svetomir , Dimou, Anastasios , Montane, Heather N , Piltin, Mara , Price, Daniel L , Khariwala, Samir S , Hui, Jane Yuet Ching , Erskine, Courtney L , Strand, Carrie A , Zahrieh, David , Dong, Haidong , Hieken, Tina J , McWilliams, Robert R , Chen, Jun , Grewal, Eric P , Johnson, Stephen , Markovic, Svetomir N. , Dimou, Anastasios , Piltin, Mara A. , Price, Daniel L. , Strand, Carrie , Dong, Haidong , Hieken, Tina J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | April 15, 2025 | Volume: 13 | Issue: 4 | Pages: e011706

10.1136/jitc-2025-011706 | PMID 40234093 Get It

Background Neoadjuvant treatment has become standard for patients with high-risk operable stage III melanoma, but the optimal regimen is unknown. Targeted therapy approaches yield high pathological response rates, while immunotherapy regimens show favorable recurrence-free survival (RFS). NeoACTIVATE was designed to address whether a neoadjuvant combination of both targeted therapy and immunotherapy might leverage the benefits of each. Methods We tested neoadjuvant treatment with 12 weeks of vemurafenib, cobimetinib, and atezolizumab for patients with BRAF-mutated (BRAFm) melanoma (cohort A) and cobimetinib and atezolizumab for patients with BRAF-wild-type (BRAFwt) melanoma (cohort B), regimens which we have shown generate a substantial major pathological response. After therapeutic lymph node dissection, patients received 24 weeks of adjuvant atezolizumab. Here, we report survival outcomes and their association with biomarkers assayed among the gut microbiome and peripheral blood immune subsets. Results With 49 months median follow-up, the median RFS was not reached for cohort A and was 40.8 months for cohort B. At 24 months after operation, 2 of 14 cohort A patients and 4 of 13 cohort B patients had experienced distant relapse. Key findings from correlative analyses included diversity, taxonomic and functional metagenomic gut microbiome signals associated with distant metastasis-free survival at 2 years. Notably, we observed a strong correlation between low microbial arginine biosynthesis (required for T-cell activation and effector function) and early distant recurrence (p=0.0005), which correlated with taxonomic differential abundance findings. Peripheral blood immune monitoring revealed increased double-positive (CD4+CD8+) T cells in patients with early recurrence. Conclusions Neoadjuvant treatment with cobimetinib and atezolizumab±vemurafenib was associated with a low rate of distant metastasis in patients with high-risk stage III melanoma. Freedom from early distant metastasis was highly associated with taxonomic differences in gut microbiome structure and with functional pathway alterations known to modulate T cell immunity. Identification of predictive biomarkers will permit optimization of neoadjuvant therapy regimens for individual patients. Trial registration number NCT03554083.
National trends in prescription drug expenditures and projections for 2025
Tichy, Eric M. , Rim, Matthew H, Cuéllar, Sandra , Tadrous, Mina , Schumock, Glen T., Johnson, Thomas J., Newell, Mary Kate, Hoffman, James M.

Mayo Clinic

American Journal of Health-System Pharmacy | April 15, 2025 | Volume: 82 | Issue: 14 | Pages: 806-821

10.1093/ajhp/zxaf092 | PMID 40263109 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2025 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2025 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, endocrine drugs, generics, specialty drugs and vaccines. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2024 were made based on a combination of quantitative analyses and expert opinion. Results In 2024, overall pharmaceutical expenditures in the US grew 10.2% compared to 2023, for a total of $805.9 billion. Utilization (a 7.9% increase) and new drugs (a 2.5% increase) drove this increase, while prices remained flat (a 0.2% decrease). Semaglutide was the top drug in 2024, followed by tirzepatide and adalimumab. Drug expenditures were $39.0 billion (a 4.9% increase) and $158.2 billion (a 14.4% increase) in nonfederal hospitals and clinics, respectively. In clinics, increased utilization drove growth, with a small contribution from new products, while prices remained flat. In nonfederal hospitals, new products, price, and new volume each contributed modestly to growth in spend. Several new drugs that will influence spending are expected to be approved in 2025. Specialty, endocrine, and cancer drugs will continue to drive expenditures. Conclusion For 2025, we expect overall prescription drug spending to rise by 9.0 to 11.0%, whereas in clinics and hospitals we anticipate an 11.0% to 13.0% increase and a 2.0% to 4.0% increase, respectively, compared to 2024. These national estimates of future pharmaceutical expenditure growth may not be representative of any health system because of the myriad of local factors that influence actual spending.
Regulatory T Cell Mimicry by a Subset of Mesenchymal GBM Stem Cells Suppresses CD4 and CD8 Cells
Johnson, Amanda , Korleski, Jack , Sall, Sophie , Li, Yunqing , Zhou, Weiqiang , Smith-Connor, Karen, Laterra, John , López-Bertoni, Hernando , Johnson, Amanda L , Korleski, Jack , Sall, Sophie , Li, Yunqing , Zhou, Weiqiang , Lopez-Bertoni, Hernando , Khela, Harmon Singh

Mayo Clinic

Cells | April 14, 2025 | Volume: 14 | Issue: 8 | Pages: 592

10.3390/cells14080592 | PMID 40277917 Get It

Attempts to activate an anti-tumor immune response in glioblastoma (GBM) have been met with many challenges due to its inherently immunosuppressive tumor microenvironment. The degree and mechanisms by which molecularly and phenotypically diverse tumor-propagating glioma stem cells (GSCs) contribute to this state are poorly defined. In this study, our multifaceted approach combining bioinformatics analyses of clinical and experimental datasets, single-cell sequencing, and the molecular and pharmacologic manipulation of patient-derived cells identified GSCs expressing immunosuppressive effectors mimicking regulatory T cells (Tregs). We showed that this immunosuppressive Treg-like (ITL) GSC state is specific to the mesenchymal GSC subset and is associated with and driven specifically by TGFβ type II receptor (TGFBR2) in contrast to TGFBR1. Transgenic TGFBR2 expression in patient-derived GBM neurospheres promoted a mesenchymal transition and induced a six-gene ITL signature consisting of CD274 (PD-L1), NT5E (CD73), ENTPD1 (CD39), LGALS1 (galectin-1), PDCD1LG2 (PD-L2), and TGFB1. This TGFBR2-driven ITL signature was identified in clinical GBM specimens, patient-derived GSCs, and systemic mesenchymal malignancies. TGFBR2high GSCs inhibited CD4+ and CD8+ T cell viability and their capacity to kill GBM cells, effects reversed by pharmacologic and shRNA-based TGFBR2 inhibition. Collectively, our data identify an immunosuppressive GSC state that is TGFBR2-dependent and susceptible to TGFBR2-targeted therapeutics.
Prolonged Adrenal Insufficiency After Failed Cryoablation and Osilodrostat for Cushing Syndrome in Nodular Adrenal Disease
Veloski, Colleen, Sturgeon, Amanda, Hallanger‐Johnson, Julie

Mayo Clinic

JCEM Case Reports | April 12, 2025 | Volume: 3 | Issue: 6 | Pages: No page available

10.1210/jcemcr/luaf091 | PMID 40303510 Get It

Abstract Nodular adrenocortical disease is an entity more commonly recognized in recent years. We present a case of bilateral adrenal nodular disease in a young woman with ACTH-independent Cushing syndrome. She was treated with medical therapies at her preference to avoid adrenal insufficiency (AI) from surgery. She developed intolerance to medical therapy. Cryoablation of the right adrenal nodule was performed after adrenal vein sampling identified the right adrenal as the dominant source of cortisol. Cortisol levels were normal while on medical therapy after cryoablation but quickly became elevated after discontinuing medical therapy. The patient was then treated with osilodrostat and ultimately developed medication-induced AI that has persisted for more than 3 years. Due to the increased availability of new medications to treat Cushing syndrome, we present our experience to educate endocrinology audiences about the unexpected responses to medications. Using osilodrostat (off-label) in this patient led to prolonged primary AI after 4 months of use and now presumed permanent AI 36 months after discontinuation of treatment.